Here’s What the Wall Street Thinks About Revolution Medicines (RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 6, Revolution Medicines, Inc. (NASDAQ:RVMD) released its financial and business update for the fiscal second quarter of 2025. The company reported advancement in its key drug Daraxonrasib, which is currently in Phase 3 trials for patients with pancreatic ductal adenocarcinoma and non-small cell lung cancer.

Wall Street is optimistic regarding this clinical-stage company, with analysts’ average 12-month price target of $72 representing 101.23% upside from the current level.

Here's What the Wall Street Thinks About Revolution Medicines (RVMD)

Recently, on August 15, Wells Fargo initiated coverage of Revolution Medicines, Inc. (NASDAQ:RVMD) with a Buy rating and a $67 price target. The firm noted that the company has worked on a de-risked profile for this drug, meaning that it has a lower chance of failure. The firm expects a positive result from the Phase 3 trial, which is due in 2026.

Revolution Medicines, Inc. (NASDAQ:RVMD) develops targeted cancer therapies for RAS-addicted cancers. They create drugs called RAS(ON) inhibitors that directly target specific RAS mutations.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.